These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 33462925)
1. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. Chen S; Yu W; Zhang K; Liu W; Chen C Hepatol Res; 2021 Apr; 51(4):482-489. PubMed ID: 33462925 [TBL] [Abstract][Full Text] [Related]
2. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680 [No Abstract] [Full Text] [Related]
3. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients. Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634 [TBL] [Abstract][Full Text] [Related]
4. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients. Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867 [No Abstract] [Full Text] [Related]
5. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history. Tang J; Huang Z; Xu J; Lv Q; Wang P Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848 [TBL] [Abstract][Full Text] [Related]
6. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. Wu B; Zhou J; Ling G; Zhu D; Long Q World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773 [TBL] [Abstract][Full Text] [Related]
7. DEB-TACE versus cTACE for unresectable HCC with B1-type bile duct invasion after successful biliary drainage: A propensity score matching analysis. Fan W; Zheng X; Zhao X; Zhu B; Wu Y; Xue M; Tang R; Huang Z; Qiao L; Lu M; Tang Y; Wu J; Li J Cancer Med; 2024 Jul; 13(13):e7419. PubMed ID: 38970348 [TBL] [Abstract][Full Text] [Related]
8. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338 [No Abstract] [Full Text] [Related]
9. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula. Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928 [TBL] [Abstract][Full Text] [Related]
10. Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302. Ikeda M; Arai Y; Inaba Y; Tanaka T; Sugawara S; Kodama Y; Aramaki T; Anai H; Morita S; Tsukahara Y; Seki H; Sato M; Kamimura K; Azama K; Tsurusaki M; Sugihara E; Miyazaki M; Kobayashi T; Sone M Liver Cancer; 2022 Sep; 11(5):440-450. PubMed ID: 36158586 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma. Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441 [TBL] [Abstract][Full Text] [Related]
12. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. Zhang ZS; Li HZ; Ma C; Xiao YD BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814 [TBL] [Abstract][Full Text] [Related]
13. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis. Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625 [TBL] [Abstract][Full Text] [Related]
14. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752 [TBL] [Abstract][Full Text] [Related]
15. Comparison of CalliSpheres Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres Duan X; Liu J; Han X; Ren J; Li H; Li F; Ju S Front Oncol; 2021; 11():793581. PubMed ID: 35127501 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. Lee IJ; Lee JH; Lee YB; Kim YJ; Yoon JH; Yin YH; Lee M; Hur S; Kim HC; Jae HJ; Chung JW Ther Adv Med Oncol; 2019; 11():1758835919866072. PubMed ID: 31447948 [TBL] [Abstract][Full Text] [Related]
18. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Fan W; Guo J; Zhu B; Wang S; Yu L; Huang W; Fan H; Li F; Wu Y; Zhao Y; Wang Y; Xue M; Wang H; Li J Eur Radiol; 2021 Nov; 31(11):8291-8301. PubMed ID: 33893536 [TBL] [Abstract][Full Text] [Related]
19. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378 [TBL] [Abstract][Full Text] [Related]
20. Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma-A Propensity Score Weighted Comparison of Efficacy and Safety. Savic LJ; Chen E; Nezami N; Murali N; Hamm CA; Wang C; Lin M; Schlachter T; Hong K; Georgiades C; Chapiro J; Laage Gaupp FM Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]